{"id":5404,"date":"2022-11-28T12:47:00","date_gmt":"2022-11-28T11:47:00","guid":{"rendered":"https:\/\/saccosystem.com\/?post_type=news&p=5404"},"modified":"2024-12-11T16:30:02","modified_gmt":"2024-12-11T15:30:02","slug":"the-akkermansia-company-how-sacco-systems-weight-management-supplement-came-into-being","status":"publish","type":"news","link":"https:\/\/saccosystem.com\/es\/news\/the-akkermansia-company-how-sacco-systems-weight-management-supplement-came-into-being\/","title":{"rendered":"The Akkermansia Company: how Sacco System’s weight-management supplement came into being"},"content":{"rendered":"\n
\n
\n

Exclusively distributed in Italy by Metagenics<\/strong>, The Akkermansia Company\u2122<\/strong> supplement<\/strong> will be available at chemist\u2019s and O.T.C. drugstores in Italy from mid-December onwards. This brand-new supplement contains a strain produced by Sacco System<\/strong> which is being put on sale for the very first time. Clinical trials have shown that this particular strain effectively combats<\/strong> the consequences of a high-fat diet (for instance, increased body fat<\/strong>, the onset of insulin-resistance<\/strong> syndrome and inflammatory states<\/strong>).<\/p>\n\n\n\n

The supplement<\/strong> was obtained by isolating<\/strong> (something achieved for the very first time in 2004) the bacterium Akkermansia muciniphila<\/em><\/strong> which, according to scientific research, helps to improve the metabolic profile associated with type-2 diabetes and obesity<\/strong>. <\/p>\n\n\n\n

In addition to 30 billion pasteurised Akkermansia muciniphila<\/em>, the supplement<\/strong> also contains chromium<\/strong> for glycaemic control as well as green-tea extract<\/strong> for weight control. A combination of these ingredients has helped to substantiate the EFSA claims.<\/p>\n\n\n\n

A close partnership between the Akkermansia Company and Sacco System<\/strong> made it possible to pinpoint a bacterial strain that was unknown until 2004 and place it on the market for the first time. The undoubted challenges of producing this anaerobic organism <\/strong>were only met thanks to the superb teamwork between the two companies. The bacteria are inactivated thanks to a special pasteurisation process which boasts the same levels of effectiveness as the live probiotic<\/strong>. <\/p>\n\n\n\n

This innovative<\/strong> product is a huge step ahead in the supplements sector in general, but is particularly seminal in the field of weight-control supplements<\/strong>.<\/p>\n\n\n\n

The video at the bottom of the article features Marco Caspani<\/strong>, CEO of the Sacco System company Centro Sperimentale del Latte, who talks us through the Akkermansia Company\u2122 production process.<\/p>\n\n\n\n

<\/div>\n\n\n\n

Akkermansia muciniphila<\/em>: Significant results in literature<\/h2>\n\n\n\n
<\/div>\n\n\n\n
    \n
  1. Strain isolated for the first time in 2004<\/strong> in the human gastrointestinal tract – group led by Professor Willlem M. de Vos, University of Wageningen.

    <\/li>\n\n\n\n
  2. Initial research<\/strong> has shown that large quantities of A. muciniphila<\/em> in the gastrointestinal tract are inversely related to obesity and type-2 diabetes<\/strong>; the consumption of A. muciniphila<\/em> does not only improve the metabolic profile of mice (reducing their body fat and insulin-resistance), but also strengthens the gut lining, which in turn lowers levels of endotoxemia and inflammation.

    <\/li>\n\n\n\n
  3. When A. muciniphila<\/em> is pasteurised<\/strong>, not only does it retain all its health benefits<\/strong>, but its healing power is actually boosted due to the presence of a protein with a heat-stable membrane and immunogenic properties<\/strong>. The Amuc_1100 protein regulates the beneficial action of the bacteria, improving the gut barrier and lowering dyslipidemia as well as reducing insulin-resistance and the accumulation of body fat.

    <\/li>\n\n\n\n
  4. A clinical trial<\/strong> (no. NCT02637115) conducted on 32 overweight\/obese and insulin-resistant individuals has shown that oral administration of A. muciniphila<\/em><\/strong>(both as a live supplement and a heat-inactivated one) is safe and well tolerated<\/strong>. The pasteurised form of the bacterium led to the improvement of a variety of metabolic parameters, such as insulin sensitivity, overall cholesterol levels and an increase in body fat and weight as well as lowering liver-inflammation markers.

    <\/li>\n\n\n\n
  5. In 2021<\/strong> the EFSA approved pasteurised A. muciniphila<\/em> as a novel food<\/em><\/strong> with a maximum dosage of 5×1010<\/sup> cells\/day for adults.
    <\/li>\n<\/ol>\n<\/div><\/div>\n<\/div><\/div>\n\n\n\n
    <\/div>\n\n\n\n

    <\/p>\n\n\n\n

    \n
    \n

    Akkermansia muciniphila:<\/em> Note sul processo produttivo<\/h2>\n\n\n\n
    <\/div>\n\n\n\n

    January 2019<\/strong><\/p>\n\n\n\n

      \n
    1. Strain arrives at Sacco and is included in our collection. It was one of the first obligate anaerobes to be included in our collection of strains. <\/li>\n<\/ol>\n\n\n\n

      <\/p>\n\n\n\n

      January-December 2019<\/strong><\/p>\n\n\n\n

        \n
      1. First small-scale pilot fermentation commenced in January (at Sacco)<\/li>\n\n\n\n
      2. First pilot fermentation on a semi-industrial scale (at CSL)<\/li>\n<\/ol>\n\n\n\n

        <\/p>\n\n\n\n

        January 2020<\/strong><\/p>\n\n\n\n

          \n
        1. Production batch of the pasteurised product for the first time (at Sacco)<\/li>\n<\/ol>\n\n\n\n

          <\/p>\n\n\n\n

          April-August 2020<\/strong><\/p>\n\n\n\n

            \n
          1. Various tests aimed at optimising the production process (at Sacco)<\/li>\n<\/ol>\n\n\n\n

            <\/p>\n\n\n\n

            September 2020<\/strong><\/p>\n\n\n\n

              \n
            1. 12000L production batch based on the previous pasteurised product batch (Sacco)<\/li>\n<\/ol>\n\n\n\n

              <\/p>\n\n\n\n

              December 2021 – February 2022<\/strong><\/p>\n\n\n\n

                \n
              1. Three production batches of 12000L and one production batch of 20000L (at CSL).
                The whole process takes place in an oxygen-deprived environment. <\/li>\n<\/ol>\n<\/div><\/div>\n<\/div><\/div>\n\n\n\n
                <\/div>\n\n\n\n
                \n
                \n

                For further information on the Akkermansia Company\u2122<\/em> weight-management supplement<\/strong>, on the Akkermansia muciniphila<\/em> bacterial strain, or just for information about our services, skills and technological know-how as regards the development of traditional and next-generation probiotic<\/strong> strains, and postbiotic formulations<\/strong>, please get in touch<\/a> with us.<\/p>\n\n\n\n

                <\/p>\n<\/div><\/div>\n<\/div><\/div>\n\n\n\n

                \n
                <\/div>\n\n\n\n
                \n